Insider Selling: PURE Bioscience (PURE) CEO Sells 41,500 Shares of Stock

PURE Bioscience (OTCMKTS:PURE) CEO Henry R. Lambert sold 41,500 shares of PURE Bioscience stock in a transaction on Friday, January 12th. The stock was sold at an average price of $0.93, for a total transaction of $38,595.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of PURE Bioscience (OTCMKTS:PURE) traded down $0.05 on Friday, hitting $0.90. 198,906 shares of the stock traded hands, compared to its average volume of 38,476. PURE Bioscience has a 52 week low of $0.83 and a 52 week high of $1.36. The firm has a market capitalization of $64.58, a P/E ratio of -8.18 and a beta of -1.48.

PURE Bioscience (OTCMKTS:PURE) last announced its quarterly earnings results on Thursday, December 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). PURE Bioscience had a negative net margin of 388.83% and a negative return on equity of 210.88%. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.65 million. equities analysts forecast that PURE Bioscience will post -0.08 earnings per share for the current fiscal year.

Separately, ValuEngine raised shares of PURE Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/12/insider-selling-pure-bioscience-pure-ceo-sells-41500-shares-of-stock.html.

PURE Bioscience Company Profile

PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply